Protocol Ledger

NCT07514338 · Phase II · RECRUITING

Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

Interventional Phase II clinical trial protocol NCT07514338 sponsored by Pharming Technologies in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-12 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07514338
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07514338
Protocol FieldVerified Registry Value
NCT IdentifierNCT07514338
Consolidated Lead SponsorPharming Technologies
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2026-06-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07514338
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria PisanaPisa, ItalyOpen Hospital Dossier ->
Radboud University Medical CenterNijmegen, NetherlandsOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI